Balaji Amines — Deep Dive Analysis

Balaji Amines — Deep Dive Analysis

Analysis date: 7 October 2026 | CMP: ₹2,175 | Model: deepseek-v4-flash (DeepSeek) | Data: Screener.in consolidated, NSE filings, NSE bhavcopy, Yahoo Finance, Tavily research

Balaji Amines is a cyclical speciality-chemicals recovery story that has already re-rated 65-95% in a year, now trading at a consensus fair value where the bull case requires margins above management's own guidance. Alongside that sit two governance disclosures in September-October 2026 that the market has largely not digested.

---

1. Quick Snapshot

---

2. Business Overview

Balaji Amines Ltd (BAL), incorporated 1988, is India's leading manufacturer of aliphatic amines and amine derivatives, with a product portfolio spanning methyl amines (MMA, DMA, TMA), ethyl amines, amine derivatives (DMAE, choline chloride, morpholine, DMF, NMP, EDA, piperazine, DETA, TETA) and speciality chemicals.

Three reporting segments: Amines, Amine Derivatives, and Speciality Chemicals.

Manufacturing: four plants — three near Solapur (Units I, III and IV at Tamalwadi/Chincholi MIDC, Maharashtra) and one near Hyderabad (Unit II, Bollaram, Telangana). The company also owns a five-star hotel in Solapur (Balaji Sarovar, managed by the Sarovar group) — a legacy diversification that has historically weighed on return ratios.

Subsidiary: Balaji Speciality Chemicals Ltd (BSCL) — a material subsidiary driving the current ₹750 Cr expansion into cyanide chemistry and EDA derivatives. Note that promoters hold 45% of BSCL, not the listed company; the stated justification is land held in promoters' names.

End-user industries: pharmaceuticals and agrochemicals together account for roughly 50-60% of sales, with the balance from paint stripping and resins, rubber chemicals, water treatment, oil refineries, mining and, increasingly, energy-transition applications (LPG blending, aerosol propellants, EV battery electrolytes).

Competitive structure: the Indian aliphatic amines market is effectively a duopoly between Balaji Amines and Alkyl Amines Chemicals. Balaji is the leader in methylamines. Chinese competition is largely absent in methylamines but has been destructive in DMF, NMP, DMC and EDA — the company had to shut its EDA plant at one point and ran it at 40-50% utilisation after restart before pivoting that capacity into higher-value derivatives (DETA, TETA, piperazine).

What the company is becoming: the growth story has shifted from commodity methylamines to (i) high-value speciality derivatives, (ii) import substitution in cyanide chemistry via BSCL, and (iii) new-age chemicals — Dimethyl Ether (DME) as an alternate fuel, and acetonitrile for pharma/agrochemical and battery applications.

---

3. Financial Performance

3.1 Annual P&L (consolidated, ₹ Cr)

3.2 Quarterly trend (consolidated, ₹ Cr)

3.3 Key takeaways — and the one number that matters most

The inflection is real, and it is margin-led. Operating margin went from 15% in Q1 FY26 to 25% in Q1 FY27 — a 1,000 bps expansion in four quarters, with net profit up 111% year-on-year.

But the volume number is alarming. Q1 FY27 consolidated volume was 21,587 MT against 27,570 MT in Q1 FY26 — down 21.7% — while revenue rose 25.6%. That means realisation per tonne rose roughly 60% (from about ₹1.33 lakh/MT to ₹2.14 lakh/MT). This is not a demand-led recovery; it is a price-led recovery.

Management's own press release is candid on this, attributing resilience partly to "adverse scenarios of West Asia's crisis" — i.e. supply-side disruption lifting global amine prices — alongside anti-dumping protection on acetonitrile and improving demand in key end-user industries.

Why this matters: price-led chemical recoveries reverse faster than volume-led ones. If West Asian supply normalises or Chinese producers return, the realisation tailwind that produced a 1,000 bps margin swing can unwind with similar speed. The company's own history shows exactly this — revenue fell from ₹2,346 Cr in FY23 to ₹1,389 Cr in FY25 as amine prices normalised, taking EPS from ₹100.47 to ₹48.62 and the stock down 53% over five years.

The long view is a cycle, not a compounding curve. FY26 revenue (₹1,419 Cr) is 40% below FY23 (₹2,346 Cr); FY26 PAT (₹169 Cr) is 58% below FY22 (₹418 Cr). TTM EPS of ₹63 is still only 55% of FY22's ₹113.71. This is a cyclical business recovering from a trough, currently priced as though the recovery is durable.

---

4. Balance Sheet

Read of the balance sheet:

• The "zero-debt" claim is standalone only. The company states "on a standalone basis, we are a zero-debt company", which is accurate. Consolidated borrowings, however, rose from ₹11 Cr to ₹133 Cr during FY26, and other liabilities jumped from ₹396 Cr to ₹633 Cr. Debt/equity is still a comfortable 0.07, but the direction has changed with the capex cycle.
• CWIP more than doubled to ₹512 Cr — this is the DME plant, the ACN expansion, the NMM project and the BSCL build all in progress simultaneously. This is the single clearest signal of the scale of what is being built.
• Reserves have grown steadily to ₹1,970 Cr, giving a book value of ₹610 per share and a P/B of 3.6x — Screener flags this as a con, and rightly: 3.6x book for an 8.7% ROE business is not cheap.

---

5. Cash Flow

The cash flow statement tells the honest version of the story. Operating cash flow has declined for three consecutive years (₹334 Cr → ₹255 Cr → ₹184 Cr) even as reported profits recovered, and free cash flow turned negative at -₹186 Cr in FY26 as capex more than doubled to ₹344 Cr. The company took on net debt to fund it.

CFO/OP of 82% in FY26 is acceptable but down from 128% in FY25 — working capital absorbed cash. On the positive side, working capital days improved from 101 to 68.8 days, which is one of the three things Screener lists as a strength.

What to watch: the capex cycle must convert into volume and earnings, or the negative FCF and rising consolidated debt become a real constraint rather than a temporary phase.

---

6. Shareholding Pattern

Screener's columns carry fiscal year-end labels; they are Mar year-ends, not December.

Three observations:

1. Promoter holding is stable at 54.56% — no dilution, no creeping acquisition. There is no promoter buying to read as a signal.
2. FIIs have been consistent sellers — from a peak of 5.27% (Sep 2024) to 3.17% (Jun 2026), a decline of more than two percentage points in seven quarters. Institutions are not accumulating this recovery.
3. The shareholder count has fallen every single quarter — from 1,44,990 (Sep 2023) to 1,11,615 (Jun 2026), a 23% decline. Retail investors have been exiting into strength; the float is consolidating into fewer hands. DII participation remains negligible at 1.58%, so this is not institutional accumulation replacing retail — it is genuine attrition.

6.1 Promoter pledge — a disclosure Screener does not surface

On 30 December 2025, three promoters pledged shares to HDFC Bank as security for credit facilities used for the principal business activities of subsidiary Balaji Speciality Chemicals:

Disclosed under Regulation 31(1) of the SEBI SAST Regulations. At ₹2,175, the pledged stake is worth roughly ₹218 Cr.

How to read it: pledging promoter shares to fund a subsidiary's expansion is common and not automatically a red flag — the facilities directly support BSCL's ₹750 Cr programme. But ~3.1% of equity encumbered is not nothing, and it means the debt that funds the subsidiary is secured partly on the listed company's shares. The relevant monitoring question is whether the pledge increases (which would signal funding stress as the capex runs) or is released (which would signal the subsidiary has secured standalone financing).

Note: Screener's shareholding table does not show this pledge, which is precisely why the NSE filings check exists in this workflow.

---

7. Growth Pipeline & Revenue Visibility

A chemicals company has no order book: revenue visibility comes from capacity on stream, product approvals and contract pricing. Here is what has actually been commissioned and what remains.

The policy tailwind that makes the ACN bet coherent: India notified a five-year anti-dumping duty on acetonitrile imports from China, Russia and Taiwan on 19 June 2025. ACN is used in pharmaceuticals, agrochemicals and — increasingly — as a battery electrolyte solvent. The new 1,440 TPM line is being commissioned into a protected market, which is a materially better setup than the company's earlier commodity plays.

BSCL's ₹750 Cr expansion has been granted Mega Project Status by the Government of Maharashtra under the Package Scheme of Incentives 2019, which brings fiscal benefits and signals state-level support.

Execution risk is concentrated in one place: the FY28 earnings upgrade story in the market rests overwhelmingly on BSCL Units I and II commissioning and ramping on time. Both are targeted for FY27. CWIP of ₹512 Cr on the FY26 balance sheet is the money already spent against that plan.

---

8. Management Commentary

From the Q1 FY27 press release (27 July 2026), Mr. D. Ram Reddy, Managing Director:

"We have commenced FY27 on a strong note, delivering healthy operational and financial performance supported by improved demand across key end-user industries and sustained execution across our businesses. Our diversified product portfolio, integrated manufacturing capabilities and strong customer relationships enabled us to effectively capitalize on operational efficiencies. This has been the leveraging point with improving market conditions while maintaining sustainable performance in the adverse scenarios of West Asia's crisis."

"During the quarter, we achieved a significant milestone with the successful commissioning of India's first commercial-scale 100,000 TPA Dimethyl Ether (DME) plant. This marks an important milestone in BAL's strategic vision to diversify into new-age chemicals and alternate fuel applications, while reinforcing our commitment towards import substitution and creating long-term value chain for our customers."

"Our integrated manufacturing platform continues to be a key competitive advantage, providing operational flexibility, supply chain reliability and cost efficiencies across product lines. At the same time, we remain focused on expanding our presence in high-value specialty chemicals and electronic-grade products, positioning the Company to benefit from structural growth opportunities in pharmaceuticals, agrochemicals, alternate fuels and the evolving EV battery chemicals ecosystem."

Guidance as reported from the earnings calls (secondary sources, attributed):

• FY27: volume growth of 10-15% with EBITDA margin of ~23%
• Medium term (stated on the Q2 FY26 call): sustainable EBITDA margins of 17.5%-22%; low utilisation at new plants, particularly battery-related chemicals, due to slow customer ramp-up and pending regulatory approvals
• 34% of energy sourced from renewable solar (FY26 BRSR), which management cites as supporting the 22-23% margin guidance

The critical observation: Q1 FY27's actual 26% EBITDA margin is above the top of the previously guided 17.5-22% band and above the current 23% target. Management is therefore guiding for margins to normalise downward from the current run-rate, not to hold. Any valuation that capitalises Q1's 26% margin is assuming management is being conservative about its own business.

---

9. Technical Analysis

9.1 Indicator panel (7 October 2026, CMP ₹2,176)

Two independent sources were used and cross-checked — a local script on NSE-sourced OHLC (253 bars) and computed indicators from the Yahoo Finance v8 daily series (253 bars). No disagreement between them exceeds 3%.

9.2 Price structure

Reference closes: five sessions ago ₹2,118.50; one month ago ₹2,566.80 (the high); three months ago ₹2,364.00; six months ago ₹1,076.50.

The structure is a strong long-term uptrend in a violent mid-cycle correction. Price is 122.9% above its March low and 30.4% above a rising 200-DMA (₹1,670 now vs ₹1,566 twenty sessions ago, +6.6%). But it has rolled over from the ₹2,566.80 high set on 7 September and is now 15.2% below it, with the 20/50/100 averages compressed into a tight ₹2,160-2,203 band around the price — a coiled battleground where the stock is currently undecided.

The volume behaviour deserves emphasis. The last five sessions averaged 7,11,371 shares — 155% above the 20-day average — and they coincided with a fall in price from ₹2,188 to ₹1,958 before the 6 October spike. That is distribution pressure at the top of the corrective leg, and it is not a constructive reading.

9.3 Key technical levels

How to read it: constructive above ₹2,160; neutral below. A close back under ₹2,160 opens the slide toward the ₹1,958-1,988 tier. A reclaim of ₹2,203 would repair the short-term trend. The 200-DMA at ₹1,670 is the line that would mark a genuine change of character.

9.4 The 6 October gap-up — what it was and what it wasn't

On 6 October the stock gapped from ₹1,957.80 to ₹2,287.70 (+16.9%) on 25.9 lakh shares — 6.35x the 10-session average and roughly 15.6x the average of the preceding nine sessions. The trigger was a US probe into alleged dumping of Chinese amine compounds.

The delivery data fundamentally changes how this should be read: delivery on that day was just 15.59%, against a 10-session average of 32.44% and against 38.9-44.2% on the three sessions immediately before it. A vertically higher price on record volume with collapsing delivery is the classic speculative-churn signature — intraday and positional flow, not investors taking delivery. The stock gave back 4.8% the following session.

It is a trade driven by the prospect of a probe becoming a duty. It is not, on this evidence, institutional accumulation.

---

10. Delivery Data, Block Deals & Insider Activity

10.1 NSE delivery data — last 10 trading sessions

Source: NSE bhavcopy (sec_bhavdata_full_*.csv), parsed from the raw BALAMINES line with series confirmed as EQ on every row. Market holidays in the window: 14 September 2026 (Ganesh Chaturthi) and 2 October 2026 (Gandhi Jayanti) — both returned HTTP 200 with the previous session's file, and were excluded by verifying the in-file DATE1 column.

Computed statistics

• Average delivery over 10 sessions: 32.44%
• Accumulation days (delivery > 40%): 1 — 1 October at 44.17%
• Distribution days (delivery < 30%): 2 — 23 September at 29.01%, and 6 October at 15.59%
• Average volume: 4,07,298 shares

Interpretation — this is the single most important table in the report for anyone considering a trade.

The constructive part: delivery was firm at 38.9-44.2% during 30 September to 5 October, precisely while the price was falling from ₹2,118 to ₹1,958. High-delivery selling into weakness means real transfers of stock are taking place at those prices rather than pure intraday churn — some genuine absorption of supply.

The alarming part: the largest volume event in the entire window — 6 October, at 6.35x the 10-session average volume and roughly 15.6x the average of the nine preceding sessions — carried the lowest delivery of the series at 15.59%. Delivery percentage falls as price rises into the spike. That is the opposite of accumulation.

Verdict on delivery: no evidence of sustained institutional accumulation in this window. One accumulation day out of ten, and the biggest price event was the weakest on delivery.

10.2 Bulk and Block Deals — Calendar 2026

Interpretation — this is the most important thing to get right in this section. Every bulk deal in calendar 2026 belongs to a high-frequency trading firm (HRTI, Junomoneta, QE Securities, AlphaGrep, NK Securities, Microcurves, Irage, Musigma, Pace, CLT), and in almost every case the same entity bought and sold a matching quantity on the same day at near-identical prices. That is prop-desk arbitrage, not accumulation. Blindly reading "bulk purchase of 2.6 lakh shares" as institutional buying would be wrong here.

There are no block deals in calendar 2026. The last block deals were in October 2022 (iShares ETF rebalancing). No genuine institutional accumulation is visible through the bulk/block route this year.

10.2 Insider and Promoter Activity

• No material insider buying or selling by promoters or KMP is disclosed for 2026 beyond the pledge creation of 30 December 2025 (Section 6.1).
• The only promoter-related filings in 2026 are routine annual Reg 31(4) disclosures.
• Promoter pledge: ~10.0 lakh shares (3.09% of equity) pledged to HDFC Bank — detailed in Section 6.1.

---

11. Forward PE Valuation

11.1 Where the stock trades today

The gap between 42.2x on FY26 actuals and 23.5x on Q1 FY27 annualised is the entire debate: which of those is the right earnings base for this business?

11.2 Building the FY27 estimate from management's own guidance

Management guides 10-15% volume growth and ~23% EBITDA margin for FY27. Applying that to a Q1 FY27 revenue run-rate of ₹461 Cr (with realisation stable and volumes ramping):

11.3 Credibility check — back-calculating the implied EBITDA margin

The workflow requires testing whether the earnings estimates baked into the market imply margins management has not guided to. Working backwards from EPS:

• Base case FY27E EPS ₹89 → PAT ₹289 Cr → pre-tax ₹391 Cr → EBITDA (PAT/0.74 + depreciation + interest − other income) ≈ ₹435 Cr → implied EBITDA margin on ₹1,850 Cr revenue = 23.5% vs guidance of ~23%. Gap: +0.5pp — consistent, no red flag.
• Bull case FY28E EPS ₹111.6 (the widely-cited bull number) → PAT ₹362 Cr → EBITDA ≈ ₹556 Cr. With revenue at a 25% CAGR from FY26 (₹2,217 Cr), implied EBITDA margin = 25.1% — roughly 2.1-3.1pp above management's 22-23% guidance band. This is the number to watch: the bull case is only achievable if BSCL's high-value derivatives deliver structurally better margins than the guided range, or if ACN/DME realisations run hotter than assumed.

Verdict of the credibility check: the base case is credible and sits inside management guidance. The bull case requires the company to outperform its own stated margin ceiling. Anyone extrapolating Q1 FY27's 26% margin across FY27-28 is above management guidance.

11.4 PEG — and why the trailing figure is meaningless here

Screener reports a PEG of -1.74, which is arithmetically correct and analytically useless: three-year profit growth is negative (-19.8%), so the ratio is not interpretable.

The forward PEG looks attractive — roughly 24.4 ÷ 65% forward EPS growth = ~0.4x — but this must be read with a warning: the forward growth rate is measured off a cyclical trough. FY22 EPS was ₹113.71; FY27E EPS of ₹89 is still below the level the company earned four years ago. Growth from a depressed base always flatters PEG. The honest framing is that this is a cyclical recovery priced at a mid-cycle multiple, not a structural compounder available at a PEG discount.

11.5 What the sell side and independent analysts say

The single most telling data point in this entire report: the average analyst price target (₹2,086) is below the current market price (₹2,175), as is the Alpha Spread consensus (₹1,780). The stock has already run past consensus fair value. Even Trendlyne's ₹2,086 target is essentially at the market.

11.6 What has to be true

At ₹2,175 the market is paying 34.5x trailing earnings and roughly 24-27x FY27E for a business with an 8.7% ROE, negative free cash flow, 40% lower revenue than four years ago, and a 53% five-year negative return. That price requires:

1. Volume growth of 10-15% to actually materialise — Q1 FY27 volumes were down 22% year-on-year, so this requires a sharp second-half recovery
2. EBITDA margin to hold at or above 23% — i.e. the realisation tailwind to persist against any normalisation of West Asian supply or Chinese exports
3. BSCL Units I and II to commission and ramp on schedule in FY27 — the entire FY28 upgrade depends on it
4. The ACN anti-dumping protection to hold through its five-year term
5. Governance overhang from the September-October 2026 disclosures to stay contained (Section 18)

---

12. Recent News & Catalysts

Positive

• Q1 FY27 results (27 July 2026): net profit +110% YoY to ₹78 Cr, EBITDA margin expanded to 26%, EPS ₹23.13. The strongest quarter in over three years.
• ACN plant commissioned (24 September 2026) — capacity enhanced to 1,440 TPM, into a market protected by a five-year anti-dumping duty on Chinese, Russian and Taiwanese acetonitrile.
• India's first commercial-scale DME plant commissioned (20 May 2026) — 1,00,000 TPA, entry into alternate-fuel and aerosol-propellant markets.
• US probe into alleged dumping of Chinese amine compounds (6 October 2026) — the stock surged 16.9% on ~10x average volume in a single session on the prospect of further trade protection.
• FY26 BRSR: 34% of energy sourced from renewable solar, supporting the 22-23% margin guidance.
• BSCL ₹750 Cr expansion with Mega Project Status from the Government of Maharashtra; both units targeted for FY27 commissioning.

Neutral / in progress

• Credit rating withdrawn by India Ratings (12-15 September 2026) — the rating on ₹195 Cr of bank loan facilities was withdrawn because of "No Due Certificates from the banks". Read carefully: this is a consequence of the company clearing its bank dues rather than a negative credit action, but it does mean the group loses ongoing third-party credit surveillance precisely as consolidated borrowings rise to ₹133 Cr.
• NMM commissioning during FY27.
• Analyst/investor meets through August 2026 and an investor presentation on 29 July 2026.
• Low utilisation at new plants, particularly battery-related chemicals, due to slow customer ramp-up and pending regulatory approvals (management commentary).

Negative / risks

• SEBI warning letter (29 September 2026) for non-disclosure of two material regulatory events — detailed in Section 18.
• DGFT Denied Entity List placement (13 August 2024) — the company's Import Export Code was blacklisted for violation of export obligations. Company states no material impact.
• FDA Maharashtra strict warning (10 January 2025) over technical-grade propylene glycol reaching pharmaceutical use.
• Volumes down 21.7% YoY in Q1 FY27 despite the earnings surge — the recovery is price-led.
• FII holding down to 3.17% from 5.27% two years ago.
• Free cash flow negative at -₹186 Cr in FY26 and consolidated borrowings up 12x.
• Chinese dumping remains the structural overhang across DMF, NMP, DMC and EDA.

---

13. Key Risks

---

14. Screener Pros & Cons

Pros

• Company is almost debt free (standalone)
• Company has been maintaining a healthy dividend payout of 20.4%
• Company's working capital requirements have reduced from 101 days to 68.8 days

Cons

• Stock is trading at 3.60 times its book value
• The company has delivered a poor sales growth of 1.64% over the past five years
• Company has a low return on equity of 9.92% over the last 3 years

Our addition: Screener's pros and cons do not capture the governance disclosures of September-October 2026, the promoter pledge, or the price-led nature of the current recovery. All three are material.

---

15. Bull vs Bear

The Bull Case

1. Operating leverage is arriving with the capex cycle nearly complete. Three plants commissioned or commissioning in FY27 (DME, ACN, NMM) plus the BSCL build. CWIP of ₹512 Cr converts to revenue-generating assets.
2. ACN is being commissioned into a protected market. A five-year anti-dumping duty on Chinese, Russian and Taiwanese acetonitrile (notified June 2025) gives the new 1,440 TPM line an unusually favourable start.
3. Q1 FY27 was the strongest quarter in over three years — margin at 26%, EPS ₹23.13, PAT +110% YoY.
4. Duopoly economics in methylamines. Balaji and Alkyl Amines control the Indian market, with Chinese competition largely absent in this product line.
5. Superior product mix emerging. Import substitution in cyanide chemistry (HCN, NaCN, EDTA) targets products currently imported, plus new-age chemicals (DME, and ACN into battery electrolytes) — genuine structural growth rather than commodity cyclicality.
6. Management guidance is achievable and the base case implies ~24x FY27E, which is not demanding for a business at an inflection if the volumes return.
7. Balance sheet capacity remains: D/E of 0.07 leaves room to fund the pipeline without distress.

The Bear Case

1. The recovery is price-led, not volume-led. Volumes fell 21.7% YoY. Realisation rose ~60%. Price-led chemical recoveries reverse violently — the company's own FY23-FY25 history proves it (revenue -41%, EPS -52%, stock -53% over five years).
2. Margins are above management's own guidance. Q1 FY27's 26% exceeds the guided 23% for FY27 and the 17.5-22% medium-term band. Management expects normalisation.
3. The average analyst price target (₹2,086) is below the current price (₹2,175). The stock has run past consensus fair value.
4. Governance disclosures in September-October 2026 are serious. SEBI formally warned the company for not disclosing a DGFT Denied Entity List order and an FDA warning letter, called the company's explanation inconsistent, and flagged possible future enforcement. That is a disclosure-culture problem, and it emerged from a complaint.
5. Free cash flow is negative (-₹186 Cr) and consolidated debt rose 12x as CWIP hit ₹512 Cr. Execution must deliver.
6. No genuine institutional accumulation. Every 2026 bulk deal is HFT arbitrage with matched buy/sell; there are no block deals; FIIs have cut holdings from 5.27% to 3.17%; the shareholder count has fallen every quarter.
7. The 6 October surge was event-driven speculation. A US probe into Chinese amine dumping is not a duty, and 360 ONE Capital has already called the reaction overdone.
8. Structurally low returns. ROCE 11%, ROE 8.7%, and a 3.6x price-to-book multiple.
9. The bull case for FY28 requires ~25% EBITDA margins — above management's guided range — or a lucky price cycle.

---

16. Final Verdict

Rating: CAUTION — fully valued after a 65-95% re-rating; wait for evidence, not narrative

Where we land: Balaji Amines is a genuinely improving business at a genuine inflection point. The ACN commissioning into an anti-dumping-protected market and the BSCL import-substitution platform are real strategic achievements, and Q1 FY27's numbers were excellent. But three things argue decisively against chasing the stock here:

1. The earnings quality is price-led. Volumes fell 22% year-on-year. Nothing about that recovery is guaranteed to persist, and this company's own history shows how hard the reversal can be.
2. The stock has already priced the good news. It is up 65% in a year, 109% in six months, and trades above the average analyst target. The 6 October spike was speculative, tied to a US probe rather than a duty.
3. Governance has become a real, not theoretical, concern. A formal SEBI warning for non-disclosure of a DGFT blacklisting and an FDA warning, with the regulator explicitly flagging future enforcement, is the kind of issue that can cap a multiple for a long time.

What would change our view (upgrade triggers):

• Q2 FY27 volumes growing 10%+ year-on-year, confirming the volume cycle has turned
• EBITDA margin holding above 23% for two consecutive quarters with volumes rising
• BSCL Unit I and II commissioning on schedule
• Release of the promoter pledge (evidence of subsidiary-level funding strength)
• Clarity that the SEBI matter has closed without further action

What would confirm the bear case:

• Realisation falling while volumes stay flat (margin compression with no volume offset)
• SEBI escalation, or further undisclosed-event revelations
• BSCL commissioning slippage into FY28
• A close below the ₹1,950-2,050 consolidation floor

Suitability by investor profile

Ideal accumulation zone if the thesis is to be owned: ₹1,600-1,850, i.e. back toward the average consensus targets and closer to the pre-spike consolidation, would give a margin of safety around the FY27 estimate. Above ₹2,200, the buyer is paying for the FY28 bull case to be delivered on schedule and at margins above management's own guidance.

---

17. Swing Trade Assessment (25-Point Checklist)

17.1 All 25 points assessed

17.2 Score: 15.5 / 24 (equivalent to ~16/25)

This is below the 17-point threshold for a swing entry. There are three outright fails — no base (7), weak delivery (18) and unconfirmed breakout (24) — and they are the three that matter most for a momentum trade. A 111% year-on-year profit jump is a genuine fundamental positive (item 17), but it is fully reflected in a stock that has already risen 66% in a year, and the tape shows speculative rather than institutional participation.

17.3 Trade setup if you insist on trading it

Honest summary for a swing trader: this is not a good entry. The fundamental news is excellent and the long-term trend is intact, but you would be buying the fourth day of an event-driven spike, in the middle of a compressed moving-average band, with delivery data showing churn rather than accumulation, at a price above average analyst fair value. The better trade is to wait for the gap to be tested — either a reclaim of ₹2,203 on real delivery, or a retest of ₹1,958 that holds.

---

18. Exchange Filings & Material Announcements

Recent NSE filings that can affect the price or the finances:

• 1 October 2026 — SEBI Warning-cum-Advisory Letter (dated 29 Sep 2026, received 30 Sep, disclosed 1 Oct). SEBI found the company non-compliant with Regulation 30 read with Schedule III of the LODR Regulations for failing to disclose two material regulatory events, called the explanation "inconsistent", warned it "to be careful in future", and said "appropriate enforcement action may be initiated" if it recurs. NSE filing

• 1 October 2026 — DGFT order placing the company on the Denied Entity List (order dated 13 August 2024). Import Export Code licence 3111001781 was blacklisted for "Violation of Export Obligation". The company had not disclosed it, stating it did not consider the letter disclosable; it submitted the disclosure only after SEBI's 29 September 2026 letter. Company states no material impact. NSE filing

• 1 October 2026 — FDA Maharashtra Directions and Warning Letter (dated 10 January 2025). Following a consignment of technical-grade Propylene Glycol reaching pharmaceutical use through a customer's onward sale, and four show cause notices, the authority administered a strict warning to the company. No penalty or prosecution was passed. NSE filing

• 24 September 2026 — Commencement of commercial production of the Acetonitrile (ACN) plant. Capacity enhanced to 1,440 TPM at Unit III, Chincholi MIDC, Solapur, with advanced technology, serving domestic and international markets. NSE filing

• 15 September 2026 — Withdrawal of credit rating by India Ratings (Ind-Ra). The rating on ₹1,950 million (₹195 Cr) of bank loan facilities was withdrawn on account of "No Due Certificates from the banks" — i.e. the facilities were cleared. Facilities covered: SBI (₹49 Cr fund-based, ₹46 Cr non-fund-based) and HDFC Bank (₹48 Cr fund-based, ₹52 Cr non-fund-based). NSE filing

• 27 July 2026 — Q1 FY27 results press release. Consolidated revenue ₹461 Cr, EBITDA ₹121 Cr (26% margin), PAT ₹78 Cr, EPS ₹23.13, volumes 21,587 MT (down from 27,570 MT). NSE filing

Corporate actions note: the company paid a dividend of ₹11 per share with an ex-date of 3 July 2026 — the fourth consecutive year at ₹11 (or ₹10 in 2023). No split or bonus has been effected in the past five years, so historical price levels and the 52-week range are directly comparable.

---

19. Disclaimer & Sources

This analysis is for information and education only. It is not investment advice and not a recommendation to buy, sell or hold. It was prepared by an AI agent (deepseek-v4-flash via Hermes Agent) from public sources. It contains forward-looking estimates that are frequently wrong. Verify all figures against company filings before acting.

Sources

• Screener.in — Balaji Amines consolidated page (logged-in, session verified at 27 sidebar items, 7 October 2026): sidebar metrics, quarterly results (Jun 2023-Jun 2026), annual P&L (FY22-FY26 + TTM), balance sheet, cash flow, shareholding pattern (Jun 2023-Jun 2026), pros and cons, peers
• NSE corporate filings (nsearchives.nseindia.com) — Q1 FY27 press release dated 27 July 2026; ACN commissioning 24 September 2026; India Ratings withdrawal 15 September 2026; SEBI warning letter, DGFT Denied Entity List order and FDA warning letter all disclosed 1 October 2026; investor presentation 29 July 2026; corporate actions history
• NSE bhavcopy — delivery and volume data (sec_bhavdata_full CSVs)
• NSE corporate actions — dividend history and record dates
• Yahoo Finance — price history and 52-week range for BALAMINES.NS (251 sessions), analyst price targets and recommendations (3 analysts)
• Trendlyne — bulk and block deal history (all 59 records), analyst consensus estimates, latest news summary on the US anti-dumping probe
• Alpha Spread — analyst price targets, three-year forecast CAGRs, Q2 FY26 earnings call transcript (management margin guidance of 17.5-22%)
• ScanX / Dhan — promoter pledge disclosures of 30 December 2025; historical return table
• Sahi / analyst summaries — FY27 guidance of 10-15% volume growth and 23% EBITDA margin
• Priyambansal (Substack) — independent bull case, FY28E EPS ₹111.6, target ₹3,123, and the BSCL/coal-gasification thesis
• HDFC Securities (historical) — promoter stake in BSCL, diversification history, end-user concentration
• CNBC-TV18 — US action against Chinese imports, 360 ONE Capital's "reaction overdone" view
• Univest — anti-dumping duty on acetonitrile from China, Russia and Taiwan (notified 19 June 2025, five-year term)
• ValuePickr forum — competitive dynamics in methylamines
• Tavily — news aggregation and cross-referencing across the above

Data limitations

• Q1 FY27 volume of 21,587 MT is consolidated; standalone was 20,619 MT. The realisation figures derived here (~₹2.14 lakh/MT vs ~₹1.33 lakh/MT) are computed from the company's own revenue and volume disclosures and are approximations.
• Product-level prices for methylamines, acetonitrile and DME are not disclosed by the company; the durability of current realisations cannot be verified from public filings.
• Analyst coverage is thin (3 analysts), so the consensus figures have wide dispersion (FY28 targets range from ₹1,334 to ₹3,327).
• The ₹9,000-10,000 Cr group capex figure referenced in one bearish source could not be verified against company disclosure and should be treated with caution; it does not reconcile with the ₹750 Cr BSCL programme and ₹512 Cr CWIP on the balance sheet.
• The promoter pledge is disclosed under SEBI SAST Regulation 31(1) and does not appear in Screener's shareholding table; it was sourced from NSE filings and secondary reporting.